拉米夫定是新一代核苷类似物 ,具有强有力的抑制乙型肝炎病毒 ( HBV)逆转录酶的作用 ,是目前认为治疗慢性乙型肝炎安全、有效的药物。自从 1998年底美国 FDA批准将拉米夫定应用于临床以来 ,该药在许多国家和地区先后得到批准应用。观察发现 ,长期服用拉米夫定有可能诱导 HBV的Y Lamivudine, a new generation of nucleoside analogues, has a potent inhibitory effect on hepatitis B virus (HBV) reverse transcriptase and is currently regarded as a safe and effective drug for the treatment of chronic hepatitis B. Since the end of 1998 the United States FDA approved the application of lamivudine in clinical, the drug has been approved in many countries and regions. Observations found that long-term use of lamivudine may induce HBV Y